Discuss MGF on glp1chat
Join the forum to discuss research with other members.
At a glance
MGF is a name used for IGF-1-related signals that appear when tissue responds to strain or injury. Researchers study cell growth and repair in this pathway, but an isolated synthetic peptide labeled MGF may not be the same molecule measured in the original tissue studies.
When a muscle or other tissue is strained, its IGF-related signaling can change as part of a repair response. MGF is a name tied to that biology, and researchers examine whether related peptide pieces influence cell growth or movement. A tissue's own splice product and a synthetic fragment in a vial may not be chemically identical. Knowing the exact sequence is necessary before a result can be connected to that preparation.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source describes tissue-repair and cell-proliferation models. Check which construct was tested before applying a finding to a vial labeled MGF.[1][8][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of MGF.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 100 mcg (0.1 mg) | 6 units (0.06 mL) |
| Week 2 | 150 mcg (0.15 mg) | 9 units (0.09 mL) |
| Week 3 | 200 mcg (0.2 mg) | 12 units (0.12 mL) |
| Week 4 | 250 mcg (0.25 mg) | 15 units (0.15 mL) |
| Weeks 5–8 | 300 mcg (0.3 mg) | 18 units (0.18 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units manageable for accuracy. For ≤10‑unit (≤0.10 mL) administrations during early titration, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support tissue repair and regenerative processes through localized growth factor signaling[3][4].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–300 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 100 mcg daily; increase by ~50 mcg weekly as tolerated.
- Target: 250–300 mcg daily by Weeks 4–8.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within approximately 30 days[4].
Storage Instructions
Proper storage preserves peptide quality[4][5].
- Lyophilized: Store at −20 °C (−4 °F) or colder for long‑term; refrigerate at 4 °C (39.2 °F) for short‑term.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[9].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs, upper arms) by at least 1–1.5 inches from prior sites to avoid irritation[10].
- Use 23–25 gauge, 5/8‑inch needles for subcutaneous administration[6].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (MGF, 5 mg each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 5 vials
- 16 weeks ≈ 8 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
Journal of Molecular Endocrinology (2003) — Expression of IGF‑I splice variants and structural genes in repair of rabbit tendon (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Source document
Sigma‑Aldrich — Storage and handling of synthetic peptides (stability and reconstitution guidelines) (opens in a new tab)www.sigmaaldrich.com
Back to overview ↑ - 05
Source document
R&D Systems — Recombinant human LR3 IGF‑I protein datasheet (storage and stability recommendations) (opens in a new tab)resources.rndsystems.com
Back to overview ↑ - 07
- 08
Research publication
Experimental Cell Research (2008) — MGF E‑peptide activates human muscle satellite cells (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection (site rotation and technique) (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.